19 September 2025 - The first new Alzheimer’s drug approved for use in Australia in 25 years, ticked off by the Therapeutic Goods Association in May, seemed to offer a flicker of hope for those with the disease.

But the decision in August by a different government body, the Pharmaceutical Benefits Advisory Council, not to recommend a subsidy for donanemab means it will remain prohibitively expensive for many, and has cast a shadow over its usage because of possible side effects.

Read The Australian article